Today: 21 May 2026
Intel stock dips in year-end trade as Nvidia’s $5 billion stake stays in focus for INTC
31 December 2025
2 mins read

Intel stock dips in year-end trade as Nvidia’s $5 billion stake stays in focus for INTC

NEW YORK, December 31, 2025, 5:02 PM ET — After-hours

  • Intel shares fell about 1% in Wednesday’s regular session and were little changed in after-hours trading.
  • Investors continue to weigh Nvidia’s newly disclosed $5 billion equity purchase in Intel via a private placement.
  • Focus turns to early-January macro data and Intel’s next quarterly update as 2026 trading begins.

Intel Corp (INTC) shares fell about 1.0% in Wednesday’s regular session to $36.90 and were little changed in after-hours trading. The stock ranged from $36.84 to $38.01 on the day, with volume around 51 million shares.

The move tracked a tech-led dip that pulled the S&P 500 down 0.73% and the Nasdaq off 0.76% in holiday-thin trading, Reuters reported. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity. Reuters

For Intel, the year-end pullback matters because the stock has become tightly linked to sentiment on big, capital-heavy turnarounds in semiconductors. Investors have been weighing how quickly Intel can stabilize finances while spending to expand manufacturing capacity.

Nvidia has purchased Intel shares worth $5 billion, Intel said in a filing on Monday, completing a transaction announced in September. Nvidia agreed to pay $23.28 per share for more than 214.7 million Intel shares in a private placement — a sale directly to an investor rather than in a public offering — after U.S. antitrust agencies cleared the investment earlier in December, Reuters reported.

At Wednesday’s close, Intel traded about 58% above Nvidia’s $23.28 entry price. On that basis, Nvidia’s stake would be worth roughly $7.9 billion, keeping the focus on whether Intel can translate new capital into operational progress.

Macro data also stayed on traders’ screens. U.S. weekly jobless claims fell to 199,000 for the week ended Dec. 27, below economists’ forecast of 220,000, a report on Wednesday showed.

Rate expectations matter for Intel because chip stocks often move with broader tech valuations, which can be sensitive to changes in borrowing costs. A lower-rate outlook typically supports growth multiples, while higher-for-longer rates can compress them.

Competitive pressure remains a backdrop. Intel faces Advanced Micro Devices in PC and server processors, while Nvidia dominates the market for AI accelerators that power many data-center builds.

Investors will be watching for any follow-up disclosures on how the Nvidia stake translates into deeper commercial or technology collaboration between the long-time rivals. They will also look for signals on whether Intel can sustain momentum as it invests in factories and advanced manufacturing capabilities.

The next major macro waypoint is the U.S. December employment report, scheduled for Jan. 9, according to the Bureau of Labor Statistics.

Company-specific attention is on Intel’s next earnings update, when executives are likely to face questions on cash flow and spending plans tied to its manufacturing push. Intel is expected to report results on Jan. 29, according to Nasdaq’s earnings calendar.

Technically, traders will also watch whether the stock holds above Wednesday’s intraday low near $36.84 as liquidity returns after the holiday week. A slip below that area would put the $35 level in focus early in 2026.

For now, Intel heads into the new year with a fresh $5 billion infusion from Nvidia and a market still dominated by AI-linked winners. The first sessions of 2026 will test whether Wednesday’s decline was year-end positioning or the start of a broader rotation away from big tech.

Stock Market Today

  • Actor Niko Foster lists Nevada mansion for $22 million
    May 21, 2026, 5:17 AM EDT. Actor Niko Foster is selling a 14,000-square-foot mansion near Las Vegas for $22 million. The home offers unobstructed views of the Las Vegas Strip and features a range of upscale amenities. Located in an exclusive community, the property stands out for its size and luxury.

Latest articles

Snowflake Heads Toward $205 BofA Level Before Earnings Next Week

Snowflake Heads Toward $205 BofA Level Before Earnings Next Week

21 May 2026
Snowflake shares fell 1.5% to $166.97 in early Thursday trading after Bank of America raised its price target to $205 and reiterated a Buy rating ahead of fiscal Q1 results due May 27. RBC cut its target earlier this week, highlighting ongoing competition in data and AI. Snowflake previously guided for Q1 product revenue of $1.262–$1.267 billion, up 27% year-over-year.
Arm jumps in premarket on AI chip hopes

Arm jumps in premarket on AI chip hopes

21 May 2026
Arm Holdings shares closed Wednesday at $256.73, up 15.05%, after Bernstein’s David Dai initiated coverage with an outperform rating and a $300 target, citing rising demand for server CPUs driven by agentic AI. The stock touched $259.44 during regular trading. U.S. markets were open; May 21 is not a listed exchange holiday. Arm’s AGI CPU has over $2 billion in expected demand for fiscal 2027 and 2028.
T1 Energy Stock Jumps 26% as Roth Pushback Turns Short-Seller Hit Into a Rally

T1 Energy Stock Jumps 26% as Roth Pushback Turns Short-Seller Hit Into a Rally

21 May 2026
T1 Energy Inc. shares jumped 26.45% to $8.70 Wednesday after heavy trading and recent volatility. The move follows a short-seller report alleging hidden Chinese ties and tax-credit risks, countered by a Roth Capital analyst’s defense and news of a major institutional stake. T1 reported a $21.4 million net loss but positive adjusted EBITDA and maintained its 2026 production guidance.
AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious
Previous Story

AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop